The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahydrofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.

TYMS allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. PNP allows separation of a nucleoside into the nucleobase and ribose phosphate for nucleotide salvage. XDH generates urate in the purine degradation pathway. Post-translational modifications of XDH convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species.

* Key recommended reading is highlighted with an asterisk

Battelli MG, Bolognesi A, Polito L. (2014) Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta, 1842 (9): 1502-17. [PMID:24882753]

Cantu-Medellin N, Kelley EE. (2013) Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how. Nitric Oxide, 34: 19-26. [PMID:23454592]

Day RO, Kamel B, Kannangara DR, Williams KM, Graham GG. (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci, 130 (23): 2167-2180. [PMID:27798228]

* Furuhashi M. (2020) New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab, 319 (5): E827-E834. [PMID:32893671]

Glander P, Hambach P, Liefeldt L, Budde K. (2012) Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clin Chim Acta, 413 (17-18): 1391-7. [PMID:21889500]

Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. (2013) On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem, 56 (8): 3148-67. [PMID:23452331]

* Okafor ON, Farrington K, Gorog DA. (2017) Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol Ther, 172: 139-150. [PMID:27916655]

1. Evenäs J, Edfeldt F, Lepistö M, Svitacheva N, Synnergren A, Lundquist B, Gränse M, Rönnholm A, Varga M, Wright J et al.. (2014) HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase. Bioorg Med Chem Lett, 24 (5): 1315-21. [PMID:24508129]

2. Gangjee A, Zhao Y, Ihnat MA, Thorpe JE, Bailey-Downs LC, Kisliuk RL. (2012) Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem, 20 (14): 4217-25. [PMID:22739090]

3. Heikkilä T, Ramsey C, Davies M, Galtier C, Stead AM, Johnson AP, Fishwick CW, Boa AN, McConkey GA. (2007) Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem, 50 (2): 186-91. [PMID:17228860]

4. Nelson PH, Eugui E, Wang CC, Allison AC. (1990) Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem, 33 (2): 833-8. [PMID:1967654]

5. Rosowsky A, Mota CE, Queener SF, Waltham M, Ercikan-Abali E, Bertino JR. (1995) 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem, 38 (5): 745-52. [PMID:7877140]

6. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul, 38: 135-52. [PMID:9762351]